StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.36−0.04 (-8.94%)

Close on Nov 17, 2026Market cap $87.79MP/E –Yield –

Outlook Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2025 it was 4.0%.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Sep 30, 20254.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q3 FY2025CQ2 2025Jun 30, 202570.8%–

More Outlook Therapeutics figures

See a number that looks wrong?